GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (XTER:JNJ) » Definitions » Cyclically Adjusted PS Ratio

Johnson & Johnson (XTER:JNJ) Cyclically Adjusted PS Ratio : 4.14 (As of Jun. 06, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Johnson & Johnson Cyclically Adjusted PS Ratio?

As of today (2024-06-06), Johnson & Johnson's current share price is €135.28. Johnson & Johnson's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €32.66. Johnson & Johnson's Cyclically Adjusted PS Ratio for today is 4.14.

The historical rank and industry rank for Johnson & Johnson's Cyclically Adjusted PS Ratio or its related term are showing as below:

XTER:JNJ' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.74   Med: 4.82   Max: 5.9
Current: 4.14

During the past years, Johnson & Johnson's highest Cyclically Adjusted PS Ratio was 5.90. The lowest was 3.74. And the median was 4.82.

XTER:JNJ's Cyclically Adjusted PS Ratio is ranked worse than
77.02% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.05 vs XTER:JNJ: 4.14

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Johnson & Johnson's adjusted revenue per share data for the three months ended in Mar. 2024 was €8.095. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €32.66 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Johnson & Johnson Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Johnson & Johnson's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Johnson & Johnson Cyclically Adjusted PS Ratio Chart

Johnson & Johnson Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.21 5.46 5.52 5.32 4.53

Johnson & Johnson Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.59 4.82 4.49 4.53 4.49

Competitive Comparison of Johnson & Johnson's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Johnson & Johnson's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Johnson & Johnson's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Johnson & Johnson's Cyclically Adjusted PS Ratio falls into.



Johnson & Johnson Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Johnson & Johnson's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=135.28/32.66
=4.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Johnson & Johnson's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Johnson & Johnson's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=8.095/131.7762*131.7762
=8.095

Current CPI (Mar. 2024) = 131.7762.

Johnson & Johnson Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 4.992 100.560 6.542
201409 5.003 100.428 6.565
201412 5.209 99.070 6.929
201503 5.681 99.621 7.515
201506 5.636 100.684 7.376
201509 5.428 100.392 7.125
201512 5.839 99.792 7.710
201603 5.599 100.470 7.344
201606 5.887 101.688 7.629
201609 5.700 101.861 7.374
201612 6.206 101.863 8.028
201703 6.031 102.862 7.726
201706 6.116 103.349 7.798
201709 6.022 104.136 7.620
201712 6.223 104.011 7.884
201803 5.940 105.290 7.434
201806 6.552 106.317 8.121
201809 6.393 106.507 7.910
201812 6.576 105.998 8.175
201903 6.565 107.251 8.066
201906 6.761 108.070 8.244
201909 7.050 108.329 8.576
201912 6.986 108.420 8.491
202003 7.011 108.902 8.484
202006 6.109 108.767 7.401
202009 6.705 109.815 8.046
202012 6.918 109.897 8.295
202103 7.015 111.754 8.272
202106 7.242 114.631 8.325
202109 7.416 115.734 8.444
202112 3.235 117.630 3.624
202203 7.977 121.301 8.666
202206 8.517 125.017 8.977
202209 7.589 125.227 7.986
202212 7.094 125.222 7.465
202303 7.490 127.348 7.750
202306 8.974 128.729 9.186
202309 7.846 129.860 7.962
202312 8.069 129.419 8.216
202403 8.095 131.776 8.095

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Johnson & Johnson  (XTER:JNJ) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Johnson & Johnson Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Johnson & Johnson's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Johnson & Johnson (XTER:JNJ) Business Description

Address
One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.

Johnson & Johnson (XTER:JNJ) Headlines